How more than a decade of tobacco research is shaping the future of cancer prevention

Scientific progress is often described through breakthroughs, such as a new discovery, a promising treatment, or a policy shift. Yet behind nearly every meaningful advance lies something far less visible: steady, cumulative research carried out over time.

For the Masonic Cancer Center (MCC), University of Minnesota, this principle is clearly reflected in tobacco regulatory science. The growing national conversation around reducing nicotine levels in cigarettes is not the product of a single study or moment. It represents more than a decade of careful investigation, collaboration, and persistence. It also illustrates how research conducted in Minnesota can influence public health far beyond state borders.

The power of long-term research

Scientific progress rarely happens overnight. In public health especially, meaningful advances require repeated studies, rigorous testing, and real-world evaluation. Decisions affecting millions of lives must be built on exceptionally strong evidence, and building that foundation takes time. 

At the University of Minnesota, researchers like MCC’s Dorothy Hatsukami, PhD, and Dana Carroll, PhD, have spent many years studying a simple but important question: What happens if the nicotine content of cigarettes is dramatically reduced?

Nicotine is the primary driver of cigarette addiction. Cigarette smoke contains thousands of toxic chemicals linked to cancer, heart disease, and respiratory illness. 

But what keeps people smoking is the nicotine in the cigarettes. Understanding how nicotine reduction affects behavior, dependence, and health outcomes has therefore been a central focus of research.

This work has spanned large clinical trials, behavioral studies, and population-level modeling efforts. Each study has added another layer of clarity, not only about whether nicotine reduction works, but how it works and how people respond.

Building the evidence base

Over time, findings from University of Minnesota researchers and collaborators have pointed to a consistent conclusion: Very low nicotine content (VLNC) cigarettes, which contain about 95 percent less nicotine, help reduce smoking, decrease cigarette dependence, and increase quit attempts.

Studies indicate that when people who smoke use cigarettes containing roughly 95 percent less nicotine than conventional cigarettes, they tend to smoke fewer cigarettes per day, experience less dependence on them, are more likely to try quitting, and are even more successful in quitting. Importantly, these effects have been observed across diverse populations, including groups historically burdened by higher rates of tobacco-related disease such as those with mental health conditions. Equally important, data has shown little evidence of the unintended consequences commonly questioned with low-nicotine cigarettes, such as people smoking cigarettes more intensely, substitution with other substances like alcohol, or a worsening of mental health symptoms. All of these commonly-questioned consequences have been very rare, limited, or entirely nonexistent in prior studies.

More recent studies have explored nicotine reduction in more realistic settings. To do this, scientists created experimental “marketplaces” reflecting today’s diverse tobacco and nicotine landscape, where non-combusted products like e-cigarettes, nicotine pouches, and medicinal nicotine are available alongside cigarettes. This allows for better understanding of how a nicotine reduction policy would impact people who smoke in the real world. 

Results from these studies show that nicotine reduction remains effective even in a complex marketplace. Participants using very low nicotine cigarettes smoked fewer combustible products, had lower exposure to harmful toxins, and were more likely to move away from conventional cigarettes. At the end of the trial, the majority of participants assigned to the very low nicotine content cigarettes, about 60 percent, indicated they would support a policy to reduce nicotine in cigarettes if it prevented youth from becoming dependent or if it helped them quit smoking. Additionally, about two-thirds of participants indicated that they would quit smoking if very low nicotine cigarettes were the only cigarettes available.

The takeaway from this research is important: Nicotine reduction does not just work in theory; it meaningfully influences behavior under real-world conditions.

From UMN research to national policy consideration

Research becomes truly transformative when it informs decisions beyond the lab. In the case of nicotine reduction, years of University-led studies have helped shape federal regulatory discussions and public health strategies.

The concept of limiting nicotine levels is supported by a substantial body of independent scientific evidence and the University of Minnesota has been a key leader in this work. Together, these studies suggest that lowering nicotine to minimally-addictive levels could help many people quit smoking and thus live healthier, longer lives. 

When we put all the data together, the forward-looking models project significant public health benefits with lower-nicotine cigarettes, including fewer premature deaths over time and many lives saved. For instance, if implemented in 2025, reducing the nicotine content in cigarettes has the potential to save up to 62 million life-years in the United States and prevent up to 2.4 million premature deaths by the year 2100.

These projections are grounded in decades of data describing how people respond to very low nicotine cigarettes, evidence generated through federally-funded, peer-reviewed research, including work conducted at the Masonic Cancer Center.   

Today, in 2026, a federal policy to reduce nicotine in all cigarettes has not yet been finalized.

Why this matters for Minnesota, and beyond

The importance of this research extends beyond tobacco policy. It highlights the broader value of sustained scientific investment at the University of Minnesota and the Masonic Cancer Center’s mission to reduce the burden of cancer through research, prevention, and community impact. 

Research conducted in Minnesota contributes to evidence shaping national and international public health strategies. Findings from campus studies inform regulatory approaches, clinical guidance, and prevention efforts that reach well beyond the state. 

This level of influence is only possible because long-term research infrastructure exists, enabling our scientists to pursue complex questions, refine methods, and respond to evolving health challenges. Tobacco use remains one of the leading causes of preventable cancer worldwide. Work that reduces smoking therefore carries implications for cancer prevention on a global scale. 

When studies reveal how product-level changes may reduce addiction, the potential benefits are far-reaching: fewer smoking-related diseases, lower healthcare costs, and healthier populations around the world. This is the often-unseen reach of academic research—that discoveries made in one place can ripple outward to affect millions, if not billions, of lives.

A story of patience and impact

At its core, this body of work reflects the quiet persistence of science. Progress built through careful testing, validation, and refinement is what allows researchers to address some of the most pressing and complex public health challenges we know of today. 

Research that tackles these topics doesn’t always capture headlines in the moment; its full impact often becomes clear later, when evidence accumulates, understanding deepens, and lives are ultimately improved. 

For the Masonic Cancer Center and the University of Minnesota, this work underscores the enduring value of sustained scientific examination. It demonstrates how knowledge generated today can help shape a healthier future, in Minnesota, across the country, and around the world.

We need your help to power this important research. Your donation fuels change. Make a gift to MCC today.